SP
Schedule 13D filing
Sermonix Pharmaceuticals, Inc. disclosed a 25.1% stake in LONA
Sermonix Pharmaceuticals, Inc. reported owning 25.1% of LeonaBio, Inc. (LONA) (3,149,470 shares) in a Schedule 13D filed Oct 28, 2026.
A 13D means the holder may push for changes at the company.
More LONA insider and Congress trades
From a public Schedule 13D, linked above. Not investment advice, and not a recommendation to buy or sell.